Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

BACKGROUND: Neoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) are the standard treatments in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Adding PD-1 inhibitor to the chemotherapy has shown significant clinical benefits in first-line treatment of adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Huilai, Tian, Yang, Li, Jiachen, Huang, Chao, Sun, Bokang, Gai, Chunyue, Li, Zhenhua, Tian, Ziqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098952/
https://www.ncbi.nlm.nih.gov/pubmed/35574384
http://dx.doi.org/10.3389/fonc.2022.864533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098952/
https://www.ncbi.nlm.nih.gov/pubmed/35574384
http://dx.doi.org/10.3389/fonc.2022.864533

Ejemplares similares